Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

GE Healthcare to Open Biotechnology Manufacturing Center in U.K.

By GE Healthcare | November 28, 2018

Scientist works in GE Healthcare manufacturing center in Stevenage, U.K. (Credit: GE Healthcare)

GE Healthcare plans to open a biotechnology manufacturing center at the Stevenage Bioscience Catalyst (SBC) Open Innovation Campus, in Stevenage, U.K.

In the first half of 2019, the center will start producing a fiber-based purification platform, which has the potential to improve efficiency in the purification steps of manufacturing biopharmaceuticals, gene therapies, and viral vectors.

The fiber-based purification platform comprises material with a unique proprietary structure. It has the potential to significantly improve process speed, flexibility, and robustness during purification, a key step in the manufacturing of biopharmaceuticals. Additional products also will be produced at the center to serve both laboratory and clinical applications.  

Opening the new facility, which incorporates 3,000 sq. ft (280 m2) of cleanroom space, will boost to 20 the number of workers at GE Healthcare’s Stevenage facility. The fiber-based purification products will be prepared in Stevenage before being further processed and finished in GE Healthcare’s existing manufacturing facility in Cardiff, Wales.

Biopharmaceuticals, such as monoclonal antibodies, are the world’s fastest-growing class of medicine. The global market for biopharmaceuticals is estimated at more than $200 billion, and the market is growing around eight percent annually1. All of the top 10 biologic drugs by global revenue use GE Healthcare technologies in their manufacture2.

The purification technology to be produced at the new facility came to GE Healthcare as part of the acquisition of Puridify, in November 2017. Puridify was founded in 2013 as a spin-out from University College London (UCL) and was based at the bio-incubator facility at the SBC, where GE Healthcare maintains an open laboratory aimed at providing SBC tenants with affordable access to advanced protein and cell analysis technologies.

(Source: GE Healthcare)

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Cambridge Pharma launches with UK plant in Cambridge Research Park
Entegris logo
Entegris opens Life Sciences Technology Center in Massachusetts
sustainability
How pharma can optimize for right-the-first-time drug manufacturing and sustainability

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards